348 related articles for article (PubMed ID: 30950164)
1. Inhibitory effects of Shati/Nat8l overexpression in the medial prefrontal cortex on methamphetamine-induced conditioned place preference in mice.
Haddar M; Uno K; Azuma K; Muramatsu SI; Nitta A
Addict Biol; 2020 May; 25(3):e12749. PubMed ID: 30950164
[TBL] [Abstract][Full Text] [Related]
2. Regulatory system of mGluR group II in the nucleus accumbens for methamphetamine-induced dopamine increase by the medial prefrontal cortex.
Haddar M; Uno K; Hamatani K; Muramatsu SI; Nitta A
Neuropsychopharmacol Rep; 2019 Sep; 39(3):209-216. PubMed ID: 31283871
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice.
Miyamoto Y; Ishikawa Y; Iegaki N; Sumi K; Fu K; Sato K; Furukawa-Hibi Y; Muramatsu S; Nabeshima T; Uno K; Nitta A
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1283-94. PubMed ID: 24559655
[TBL] [Abstract][Full Text] [Related]
4. Methamphetamine induces Shati/Nat8L expression in the mouse nucleus accumbens via CREB- and dopamine D1 receptor-dependent mechanism.
Uno K; Miyazaki T; Sodeyama K; Miyamoto Y; Nitta A
PLoS One; 2017; 12(3):e0174196. PubMed ID: 28319198
[TBL] [Abstract][Full Text] [Related]
5. Deletion of SHATI/NAT8L increases dopamine D1 receptor on the cell surface in the nucleus accumbens, accelerating methamphetamine dependence.
Toriumi K; Kondo M; Nagai T; Hashimoto R; Ohi K; Song Z; Tanaka J; Mouri A; Koseki T; Yamamori H; Furukawa-Hibi Y; Mamiya T; Fukushima T; Takeda M; Nitta A; Yamada K; Nabeshima T
Int J Neuropsychopharmacol; 2014 Mar; 17(3):443-53. PubMed ID: 24246274
[TBL] [Abstract][Full Text] [Related]
6. A novel molecule "shati" is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference.
Niwa M; Nitta A; Mizoguchi H; Ito Y; Noda Y; Nagai T; Nabeshima T
J Neurosci; 2007 Jul; 27(28):7604-15. PubMed ID: 17626222
[TBL] [Abstract][Full Text] [Related]
7. Impairment of cognitive function induced by Shati/Nat8l overexpression in the prefrontal cortex of mice.
Haddar M; Azuma K; Izuo N; Kyosuke U; Asano T; Muramatsu SI; Nitta A
Behav Brain Res; 2021 Jan; 397():112938. PubMed ID: 32998043
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of dopamine and glutamate release in the prefrontal cortex and nucleus accumbens following methamphetamine self-administration and during reinstatement in rats.
Parsegian A; See RE
Neuropsychopharmacology; 2014 Mar; 39(4):811-22. PubMed ID: 23995583
[TBL] [Abstract][Full Text] [Related]
9. Deletion of SHATI/NAT8L decreases the N-acetylaspartate content in the brain and induces behavioral deficits, which can be ameliorated by administering N-acetylaspartate.
Toriumi K; Mamiya T; Song Z; Honjo T; Watanabe H; Tanaka J; Kondo M; Mouri A; Kim HC; Nitta A; Fukushima T; Nabeshima T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2108-17. PubMed ID: 26361739
[TBL] [Abstract][Full Text] [Related]
10. Striatal N-Acetylaspartate Synthetase Shati/Nat8l Regulates Depression-Like Behaviors via mGluR3-Mediated Serotonergic Suppression in Mice.
Miyamoto Y; Iegaki N; Fu K; Ishikawa Y; Sumi K; Azuma S; Uno K; Muramatsu SI; Nitta A
Int J Neuropsychopharmacol; 2017 Dec; 20(12):1027-1035. PubMed ID: 29020418
[TBL] [Abstract][Full Text] [Related]
11. Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons.
Sumi K; Uno K; Matsumura S; Miyamoto Y; Furukawa-Hibi Y; Muramatsu S; Nabeshima T; Nitta A
Neuroreport; 2015 Sep; 26(13):740-6. PubMed ID: 26164607
[TBL] [Abstract][Full Text] [Related]
12. A Single Medical Marker for Diagnosis of Methamphetamine Addiction - DNA Methylation of SHATI/NAT8L Promoter Sites from Patient Blood.
Yuka K; Nishizawa D; Hasegawa J; Uno K; Miyanishi H; Ujike H; Ozaki N; Inada T; Iwata N; Sora I; Iyo M; Yamada M; Kondo N; Won MJ; Naruse N; Uehara-Aoyama K; Ikeda K; Nitta A
Curr Pharm Des; 2020; 26(2):260-264. PubMed ID: 31924153
[TBL] [Abstract][Full Text] [Related]
13. Levo-tetrahydropalmatine attenuates methamphetamine reward behavior and the accompanying activation of ERK phosphorylation in mice.
Su H; Sun T; Wang X; Du Y; Zhao N; Zhu J; Yan J; Chen T; Yun K
Neurosci Lett; 2020 Jan; 714():134416. PubMed ID: 31398456
[TBL] [Abstract][Full Text] [Related]
14. Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens.
Fu K; Lin H; Miyamoto Y; Wu C; Yang J; Uno K; Nitta A
Psychopharmacology (Berl); 2016 Mar; 233(5):831-40. PubMed ID: 26621348
[TBL] [Abstract][Full Text] [Related]
15. S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.
Faiman MD; Kaul S; Latif SA; Williams TD; Lunte CE
Neuropharmacology; 2013 Dec; 75():95-105. PubMed ID: 23891816
[TBL] [Abstract][Full Text] [Related]
16. Deletion of VGLUT2 in midbrain dopamine neurons attenuates dopamine and glutamate responses to methamphetamine in mice.
Shen H; Chen K; Marino RAM; McDevitt RA; Xi ZX
Pharmacol Biochem Behav; 2021 Mar; 202():173104. PubMed ID: 33444596
[TBL] [Abstract][Full Text] [Related]
17. Behavioral impairment in SHATI/NAT8L knockout mice via dysfunction of myelination development.
Sumi K; Uno K; Noike H; Tomohiro T; Hatanaka Y; Furukawa-Hibi Y; Nabeshima T; Miyamoto Y; Nitta A
Sci Rep; 2017 Dec; 7(1):16872. PubMed ID: 29203794
[TBL] [Abstract][Full Text] [Related]
18. Levo-tetrahydropalmatine attenuates the development and expression of methamphetamine-induced locomotor sensitization and the accompanying activation of ERK in the nucleus accumbens and caudate putamen in mice.
Zhao N; Chen Y; Zhu J; Wang L; Cao G; Dang Y; Yan C; Wang J; Chen T
Neuroscience; 2014 Jan; 258():101-10. PubMed ID: 24269936
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin-1 downregulation in the nucleus accumbens promotes methamphetamine-primed reinstatement in mice.
Huang M; Yan C; Yang X; Zhou X; Lv W; Guo N; Li Y; Bai J
Neuropharmacology; 2018 Sep; 139():117-123. PubMed ID: 29981334
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
